RU2022106357A - Противораковые рнк-вакцины - Google Patents
Противораковые рнк-вакцины Download PDFInfo
- Publication number
- RU2022106357A RU2022106357A RU2022106357A RU2022106357A RU2022106357A RU 2022106357 A RU2022106357 A RU 2022106357A RU 2022106357 A RU2022106357 A RU 2022106357A RU 2022106357 A RU2022106357 A RU 2022106357A RU 2022106357 A RU2022106357 A RU 2022106357A
- Authority
- RU
- Russia
- Prior art keywords
- peptide
- peptide epitopes
- epitope
- mrnas
- mrna
- Prior art date
Links
- 230000001093 anti-cancer Effects 0.000 title claims 2
- 229960005486 vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 108020004999 messenger RNA Proteins 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 4
- 108700026244 Open Reading Frames Proteins 0.000 claims 4
- 210000001744 T-lymphocyte Anatomy 0.000 claims 4
- 239000000427 antigen Substances 0.000 claims 4
- 102000036639 antigens Human genes 0.000 claims 4
- 108091007433 antigens Proteins 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 108700021021 mRNA Vaccine Proteins 0.000 claims 3
- 229940126582 mRNA vaccine Drugs 0.000 claims 3
- 230000035772 mutation Effects 0.000 claims 2
- 108700020796 Oncogene Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001164—GTPases, e.g. Ras or Rho
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Claims (6)
1. Противораковая мРНК-вакцина, содержащая:
липидную наночастицу, содержащую что-либо одно или более из перечисленного ниже:
(a) одна или более мРНК, каждая из которых содержит одну или более открытых рамок считывания, кодирующих 1-500 пептидных эпитопов, которые представляют собой персонализированные раковые антигены, и универсальный Т-клеточный эпитоп II типа;
(b) одна или более мРНК, каждая из которых содержит открытую рамку считывания, кодирующую пептид активирующей мутации онкогена, при этом указанная мРНК необязательно дополнительно содержит универсальный Т-клеточный эпитоп II типа;
(c) одна или более мРНК, каждая из которых содержит открытую рамку считывания, кодирующую пептидный эпитоп ракового антигена, при этом указанная мРНК-вакцина кодирует 5-100 пептидных эпитопов и по меньшей мере два из указанных пептидных эпитопов представляют собой персонализированные раковые антигены, при этом указанная мРНК необязательно дополнительно содержит универсальный Т-клеточный эпитоп II типа; и/или
(d) одна или более мРНК, каждая из которых содержит открытую рамку считывания, кодирующую пептидный эпитоп ракового антигена, при этом указанная мРНК-вакцина кодирует 5-100 пептидных эпитопов и по меньшей мере три из указанных пептидных эпитопов представляют собой комплексные варианты, а по меньшей мере два из указанных пептидных эпитопов представляют собой точечные мутации, при этом указанная мРНК необязательно дополнительно содержит универсальный Т-клеточный эпитоп II типа.
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453465P | 2017-02-01 | 2017-02-01 | |
| US201762453444P | 2017-02-01 | 2017-02-01 | |
| US62/453,465 | 2017-02-01 | ||
| US62/453,444 | 2017-02-01 | ||
| US201762558238P | 2017-09-13 | 2017-09-13 | |
| US62/558,238 | 2017-09-13 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019127381A Division RU2768829C2 (ru) | 2017-02-01 | 2017-10-26 | Противораковые рнк-вакцины |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2022106357A true RU2022106357A (ru) | 2022-03-24 |
Family
ID=63040027
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2022106357A RU2022106357A (ru) | 2017-02-01 | 2017-10-26 | Противораковые рнк-вакцины |
| RU2019127381A RU2768829C2 (ru) | 2017-02-01 | 2017-10-26 | Противораковые рнк-вакцины |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2019127381A RU2768829C2 (ru) | 2017-02-01 | 2017-10-26 | Противораковые рнк-вакцины |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20190351040A1 (ru) |
| EP (1) | EP3576751A4 (ru) |
| JP (2) | JP2020506189A (ru) |
| KR (2) | KR20190120233A (ru) |
| CN (1) | CN110505877A (ru) |
| AU (1) | AU2017397458A1 (ru) |
| CA (1) | CA3052255A1 (ru) |
| MA (1) | MA47401A (ru) |
| NZ (1) | NZ755780A (ru) |
| RU (2) | RU2022106357A (ru) |
| SG (2) | SG10202108307YA (ru) |
| WO (1) | WO2018144082A1 (ru) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP3981437B1 (en) | 2014-04-23 | 2024-10-09 | ModernaTX, Inc. | Nucleic acid vaccines |
| US11007260B2 (en) | 2015-07-21 | 2021-05-18 | Modernatx, Inc. | Infectious disease vaccines |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| WO2017031232A1 (en) | 2015-08-17 | 2017-02-23 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| WO2017070626A2 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Respiratory virus vaccines |
| JP2018531290A (ja) | 2015-10-22 | 2018-10-25 | モデルナティーエックス， インコーポレイテッド | 性感染症ワクチン |
| BR112018008051A2 (pt) | 2015-10-22 | 2018-11-13 | Modernatx Inc | vacinas de ácido nucleico para vírus de varicella zoster (vzv) |
| WO2017070613A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP3364950A4 (en) | 2015-10-22 | 2019-10-23 | ModernaTX, Inc. | VACCINES AGAINST TROPICAL DISEASES |
| EP3386484B1 (en) | 2015-12-10 | 2022-03-30 | ModernaTX, Inc. | Compositions and methods for delivery of therapeutic agents |
| US10465190B1 (en) | 2015-12-23 | 2019-11-05 | Modernatx, Inc. | In vitro transcription methods and constructs |
| CN114751950A (zh) | 2016-03-18 | 2022-07-15 | 免疫传感器公司 | 环二核苷酸化合物及使用方法 |
| EP3777881A1 (en) * | 2016-04-22 | 2021-02-17 | CureVac AG | Rna encoding a tumor antigen |
| IL263079B2 (en) | 2016-05-18 | 2024-05-01 | Modernatx Inc | Relaxin-encoding polynucleotides |
| MA45052A (fr) | 2016-05-18 | 2019-03-27 | Modernatx Inc | Polynucléotides codant pour jagged1 pour le traitement du syndrome d'alagille |
| EP3512944B1 (en) | 2016-09-14 | 2022-07-06 | ModernaTX, Inc. | High purity rna compositions and methods for preparation thereof |
| WO2018075980A1 (en) | 2016-10-21 | 2018-04-26 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| US11103578B2 (en) | 2016-12-08 | 2021-08-31 | Modernatx, Inc. | Respiratory virus nucleic acid vaccines |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| AU2018219862B2 (en) * | 2017-02-07 | 2020-09-17 | Nant Holding IP, LLC | Maximizing T-cell memory and compositions and methods therefor |
| MA47515A (fr) | 2017-02-16 | 2019-12-25 | Modernatx Inc | Compositions immunogènes très puissantes |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11576961B2 (en) | 2017-03-15 | 2023-02-14 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| US11045540B2 (en) | 2017-03-15 | 2021-06-29 | Modernatx, Inc. | Varicella zoster virus (VZV) vaccine |
| WO2018170260A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Respiratory syncytial virus vaccine |
| MA47790A (fr) | 2017-03-17 | 2021-05-05 | Modernatx Inc | Vaccins à base d'arn contre des maladies zoonotiques |
| MA48047A (fr) | 2017-04-05 | 2020-02-12 | Modernatx Inc | Réduction ou élimination de réponses immunitaires à des protéines thérapeutiques administrées par voie non intraveineuse, par exemple par voie sous-cutanée |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036683A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | ANALYTICAL METHODS BY HPLC |
| WO2019036685A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | METHODS FOR HPLC ANALYSIS |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| AU2018326799A1 (en) | 2017-08-31 | 2020-02-27 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| MA50253A (fr) | 2017-09-14 | 2020-07-22 | Modernatx Inc | Vaccins à arn contre le virus zika |
| MA54676A (fr) | 2018-01-29 | 2021-11-17 | Modernatx Inc | Vaccins à base d'arn contre le vrs |
| CA3104673A1 (en) * | 2018-06-27 | 2020-01-02 | Modernatx, Inc. | Personalized cancer vaccine epitope selection |
| JP2022501367A (ja) | 2018-09-20 | 2022-01-06 | モデルナティエックス インコーポレイテッドModernaTX, Inc. | 脂質ナノ粒子の調製及びその投与方法 |
| MA54192A (fr) * | 2018-11-07 | 2021-09-15 | Modernatx Inc | Vaccins à arn contre le cancer |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| TW202043272A (zh) * | 2019-01-14 | 2020-12-01 | 美商建南德克公司 | 使用pd-1軸結合拮抗劑及rna疫苗治療癌症之方法 |
| US11351242B1 (en) | 2019-02-12 | 2022-06-07 | Modernatx, Inc. | HMPV/hPIV3 mRNA vaccine composition |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| MA55037A (fr) | 2019-02-20 | 2021-12-29 | Modernatx Inc | Variants d'arn polymérase pour le coiffage co-transcriptionnel |
| WO2020190750A1 (en) | 2019-03-15 | 2020-09-24 | Modernatx, Inc. | Hiv rna vaccines |
| WO2020242720A1 (en) * | 2019-05-02 | 2020-12-03 | University Of Florida Research Foundation, Inc. | Compositions for treatment of diffuse intrinsic pontine glioma |
| JP2022535006A (ja) * | 2019-05-31 | 2022-08-04 | モデルナティエックス インコーポレイテッド | 増殖ｔ細胞アッセイ |
| CN110172480B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 双抗原表位融合基因重组慢病毒载体、抗原提呈细胞和ctl细胞及其构建方法和应用 |
| CN110172089B (zh) * | 2019-06-11 | 2020-01-07 | 北京鼎成肽源生物技术有限公司 | 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用 |
| WO2021099906A1 (en) | 2019-11-18 | 2021-05-27 | Janssen Biotech, Inc. | Vaccines based on mutant calr and jak2 and their uses |
| WO2021119418A1 (en) * | 2019-12-11 | 2021-06-17 | Vanderbilt University | Methods of synthesizing mrna and functional proteins from synthetic double stranded dna |
| EP4096720A2 (en) * | 2020-01-30 | 2022-12-07 | ModernaTX, Inc. | Mrnas encoding metabolic reprogramming polypeptides and uses thereof |
| KR20220136378A (ko) * | 2020-01-31 | 2022-10-07 | 제넨테크, 인크. | Pd-1 축 결합 길항제 및 rna 백신을 이용하여 네오에피토프-특이적 t 세포를 유도하는 방법 |
| WO2021158996A1 (en) * | 2020-02-05 | 2021-08-12 | University Of Florida Research Foundation, Incorporated | Rna-loaded nanoparticles and use thereof for the treatment of cancer |
| CA3170069C (en) * | 2020-03-11 | 2024-06-04 | Edward Asirvatham | Surfactants for healthcare products |
| EP4136096A1 (en) * | 2020-04-17 | 2023-02-22 | The Francis Crick Institute Limited | Antigen pool |
| EP3901260A1 (en) | 2020-04-22 | 2021-10-27 | BioNTech RNA Pharmaceuticals GmbH | Coronavirus vaccine |
| US11130787B2 (en) * | 2020-06-11 | 2021-09-28 | MBF Therapeutics, Inc. | Alphaherpesvirus glycoprotein d-encoding nucleic acid constructs and methods |
| KR20230034333A (ko) | 2020-07-02 | 2023-03-09 | 라이프 테크놀로지스 코포레이션 | 트리뉴클레오티드 캡 유사체, 제조 및 이의 용도 |
| EP4194006A1 (en) * | 2020-08-04 | 2023-06-14 | Progeneer Inc. | Mrna vaccine comprising adjuvant capable of kinetic control |
| KR20230066000A (ko) | 2020-08-12 | 2023-05-12 | 액팀 테라퓨틱스, 인코퍼레이티드 | 면역자극성 박테리아-기초 백신, 치료제, 및 rna 전달 플랫폼 |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| JP2023549592A (ja) | 2020-10-20 | 2023-11-28 | エスティー ファーム カンパニー リミテッド | ５’－キャッピングされたｒｎａ合成用オリゴヌクレオチド |
| WO2022087424A1 (en) * | 2020-10-22 | 2022-04-28 | The Regents Of The University Of California | Monoamine oxidase blockade therapy for treating cancer through regulating tumor associated macrophages (tams) |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| WO2022140278A1 (en) * | 2020-12-21 | 2022-06-30 | University Of Florida Research Foundation, Inc. | Multilamellar rna nanoparticle vaccine against cancer |
| CN114717229B (zh) * | 2021-01-05 | 2024-09-10 | 麦塞拿治疗(香港)有限公司 | 治疗性mRNA的无细胞和无载体体外RNA转录方法和核酸分子 |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| US20240181030A1 (en) * | 2021-03-26 | 2024-06-06 | Modernatx, Inc. | Pertussis vaccine |
| NL2028681B1 (en) * | 2021-04-02 | 2022-10-17 | Nutcracker Therapeutics Inc | Materials and methods for generating antigen-specific t cells and treating diseases |
| CN113186285B (zh) * | 2021-05-10 | 2022-05-24 | 深圳市展行生物有限公司 | 一种辅助诊断胃癌的方法及其使用的miRNA组合 |
| CN113577258B (zh) * | 2021-07-31 | 2024-04-16 | 山东兴瑞生物科技有限公司 | 一种双靶点mRNA疫苗及其制备方法 |
| CN115703714A (zh) * | 2021-08-13 | 2023-02-17 | 广州谷森制药有限公司 | 新型阳离子脂质化合物 |
| EP4147713A1 (en) * | 2021-09-13 | 2023-03-15 | OncoDNA | A rna vaccine comprising an rna pool generated from a double-stranded dna pool |
| IL311298A (en) | 2021-09-13 | 2024-05-01 | Oncodna | An RNA vaccine containing a pool of RNA produced from a pool of double-stranded DNA |
| EP4147712A1 (en) | 2021-09-13 | 2023-03-15 | OncoDNA | Method to generate a double-stranded dna pool encoding neoantigens of a tumor of a patient |
| WO2023086796A2 (en) | 2021-11-09 | 2023-05-19 | Actym Therapeutics, Inc. | Immunostimulatory bacteria for converting macrophages into a phenotype amenable to treatment, and companion diagnostic for identifying subjects for treatment |
| EP4458843A1 (en) * | 2021-12-31 | 2024-11-06 | Guangzhou National Laboratory | Mrna vaccine |
| US11878055B1 (en) | 2022-06-26 | 2024-01-23 | BioNTech SE | Coronavirus vaccine |
| WO2024026490A1 (en) * | 2022-07-28 | 2024-02-01 | Sqz Biotechnologies Company | Polynucleotides encoding linked antigens and uses thereof |
| CN115992152A (zh) * | 2022-09-22 | 2023-04-21 | 浙江大学医学院附属第一医院 | 一种用于乙型肝炎病毒治疗性mRNA疫苗及其制备方法与应用 |
| WO2024075851A1 (ja) * | 2022-10-07 | 2024-04-11 | 国立大学法人 筑波大学 | 核酸構築物およびタンパク複合体の設計方法および製造方法 |
| WO2024086609A2 (en) * | 2022-10-19 | 2024-04-25 | Kalivir Immunotherapeutics, Inc. | Nucleic acids encoding soluble pd-1 and il-12 and uses thereof |
| WO2024097257A1 (en) * | 2022-10-31 | 2024-05-10 | Gritstone Bio, Inc. | Combination panel cell-free dna monitoring |
| WO2024097874A1 (en) * | 2022-11-03 | 2024-05-10 | Modernatx, Inc. | Chemical stability of mrna |
| EP4364752A1 (en) | 2022-11-07 | 2024-05-08 | OncoDNA | Improved vaccine |
| CN116970614A (zh) * | 2022-12-29 | 2023-10-31 | 达冕疫苗(广州)有限公司 | 编码ny-eso-1的核糖核酸疫苗的组合物和方法 |
| WO2024153000A1 (en) * | 2023-01-17 | 2024-07-25 | The University Of Hong Kong | Cancer immunotherapy by delivery of mrna |
| CN116585342B (zh) * | 2023-05-23 | 2024-08-16 | 源生生物科技(青岛)有限责任公司 | 包含miRNA的活性成分及其应用 |
| CN118389553A (zh) * | 2024-03-01 | 2024-07-26 | 中国科学技术大学 | 免疫增效rna分子及其组合物、疫苗与试剂盒 |
| CN117883558B (zh) * | 2024-03-15 | 2024-06-14 | 山东兴瑞生物科技有限公司 | 靶向肝肿瘤个性化mRNA疫苗的制备方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010037408A1 (en) * | 2008-09-30 | 2010-04-08 | Curevac Gmbh | Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof |
| CN105648056A (zh) * | 2010-05-14 | 2016-06-08 | 综合医院公司 | 鉴定肿瘤特异性新抗原的组合物和方法 |
| WO2012159643A1 (en) * | 2011-05-24 | 2012-11-29 | Biontech Ag | Individualized vaccines for cancer |
| HRP20230443T1 (hr) * | 2011-05-24 | 2023-09-15 | BioNTech SE | Individualizirana cjepiva protiv raka |
| ES2659264T3 (es) * | 2011-08-16 | 2018-03-14 | Taiho Pharmaceutical Co., Ltd. | Agente antitumoral y método para pronosticar el efecto terapéutico para pacientes con cáncer colorrectal con mutación de KRAS |
| US20140255472A1 (en) * | 2011-08-31 | 2014-09-11 | Andrew Geall | Pegylated liposomes for delivery of immunogen-encoding rna |
| US9192651B2 (en) * | 2012-04-02 | 2015-11-24 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of secreted proteins |
| AU2014233424B2 (en) * | 2013-03-15 | 2017-03-16 | The Trustees Of The University Of Pennsylvania | Vaccines with biomolecular adjuvants |
| CA2925658C (en) * | 2013-10-01 | 2022-12-06 | Mie University | Long chain antigen containing interepitope sequence that promotes antigen presentation to t cells |
| CA2955250A1 (en) * | 2014-07-16 | 2016-01-21 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
| EP3603661A3 (en) * | 2015-04-22 | 2020-04-01 | CureVac AG | Rna containing composition for treatment of tumor diseases |
| EP3307305A4 (en) * | 2015-06-10 | 2019-05-22 | Modernatx, Inc. | TARGETED ADAPTIVE VACCINES |
| US20190008938A1 (en) * | 2015-07-30 | 2019-01-10 | Modernatx, Inc. | Concatemeric peptide epitope rnas |
| US20180318409A1 (en) * | 2015-10-22 | 2018-11-08 | Modernatx, Inc. | Cancer vaccines |
| CA3042015A1 (en) * | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
-
2017
- 2017-10-26 RU RU2022106357A patent/RU2022106357A/ru unknown
- 2017-10-26 CN CN201780089255.1A patent/CN110505877A/zh active Pending
- 2017-10-26 KR KR1020197025539A patent/KR20190120233A/ko active Application Filing
- 2017-10-26 US US16/482,844 patent/US20190351040A1/en active Pending
- 2017-10-26 SG SG10202108307YA patent/SG10202108307YA/en unknown
- 2017-10-26 JP JP2019541415A patent/JP2020506189A/ja active Pending
- 2017-10-26 NZ NZ755780A patent/NZ755780A/en unknown
- 2017-10-26 AU AU2017397458A patent/AU2017397458A1/en active Pending
- 2017-10-26 CA CA3052255A patent/CA3052255A1/en active Pending
- 2017-10-26 MA MA047401A patent/MA47401A/fr unknown
- 2017-10-26 RU RU2019127381A patent/RU2768829C2/ru active
- 2017-10-26 EP EP17894869.1A patent/EP3576751A4/en active Pending
- 2017-10-26 SG SG11201906895WA patent/SG11201906895WA/en unknown
- 2017-10-26 WO PCT/US2017/058595 patent/WO2018144082A1/en unknown
- 2017-10-26 KR KR1020247024776A patent/KR20240117650A/ko active Search and Examination
-
2023
- 2023-09-08 JP JP2023146197A patent/JP2023164537A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA47401A (fr) | 2021-05-05 |
| EP3576751A1 (en) | 2019-12-11 |
| US20190351040A1 (en) | 2019-11-21 |
| CN110505877A (zh) | 2019-11-26 |
| KR20240117650A (ko) | 2024-08-01 |
| JP2023164537A (ja) | 2023-11-10 |
| SG11201906895WA (en) | 2019-08-27 |
| NZ755780A (en) | 2023-10-27 |
| KR20190120233A (ko) | 2019-10-23 |
| WO2018144082A1 (en) | 2018-08-09 |
| SG10202108307YA (en) | 2021-08-30 |
| RU2019127381A3 (ru) | 2021-06-17 |
| RU2768829C2 (ru) | 2022-03-24 |
| RU2019127381A (ru) | 2021-03-02 |
| JP2020506189A (ja) | 2020-02-27 |
| AU2017397458A1 (en) | 2019-08-15 |
| EP3576751A4 (en) | 2021-08-04 |
| CA3052255A1 (en) | 2018-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2022106357A (ru) | Противораковые рнк-вакцины | |
| MX2021000193A (es) | Selección de epítopos de vacunas personalizadas contra el cáncer. | |
| MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
| WO2017136820A3 (en) | Fabs-in-tandem immunoglobulin and uses thereof | |
| WO2017123636A8 (en) | Dosage and administration of anti-c5 antibodies for treatment | |
| EA201991763A1 (ru) | Конъюгаты антитела к ccr7 и лекарственного средства | |
| EA201791150A1 (ru) | Новые пептиды и комбинации пептидов для применения в иммунотерапии гепатоклеточной карциномы (гкк) и других видов рака | |
| EP3792628A3 (en) | Methods for predicting the usefulness of neoantigens for immunotherapy | |
| EA200900795A1 (ru) | Вакцина | |
| EA201790239A1 (ru) | Молекула-носитель для антигенов | |
| MY187161A (en) | Antibodies that potently neutralize hepatitis b virus and uses thereof | |
| PH12017500890A1 (en) | Antibody drug conjugates | |
| WO2011163401A3 (en) | Colon and pancreas cancer specific antigens and antibodies | |
| MX2019002968A (es) | Un complejo novedoso que comprende un peptido penetrante de celulas, una carga y un agonista de peptido de tlr para tratamiento de cancer colorrectal. | |
| WO2017210579A8 (en) | Compositions and methods for tumor vaccination and immunotherapy involving her2/neu | |
| WO2016116905A9 (en) | Cmv antigens and uses thereof | |
| WO2017152146A3 (en) | Compositions and methods for inducing hiv-1 antibodies | |
| EA201400914A1 (ru) | Ротавирусная субъединичная вакцина и способы ее получения и применения | |
| WO2016149643A3 (en) | Fusion proteins comprising modified alpha virus surface glycoproteins and tumor associated antigen and methods thereof | |
| EA202091116A1 (ru) | Наночастицы, содержащие синтетические варианты ганглиозида gm3, в качестве адъювантов в вакцинах | |
| CY1125328T1 (el) | Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων | |
| Bayó et al. | Vaccines for non-viral cancer prevention | |
| CY1124813T1 (el) | Καινοτομα πεπτιδια και συνδυασμος πεπτιδιων για χρηση στην ανοσοθεραπεια εναντι του ηπατοκυτταρικου καρκινωματος (hcc) και αλλων μορφων καρκινου | |
| JP2017528116A5 (ru) | ||
| MX2019007924A (es) | Vacunas contra la influenza. |